| ||||||||||||||
|
|
|||||||||||||
Department of Anesthesiology, University of Occupational and Environmental Health, Kitakyushu, Japan
Address correspondence and reprint requests to Masanori Ogata, MD, Department of Anesthesiology, University of Occupational and Environmental Health, 11-1 Iseigaoka Yahata-nishi-ku Kitakyushu, 807-8555, Japan. Address e-mail to mogata{at}med.uoeh-u.ac.jp
The production of proinflammatory cytokines, such as tumor necrosis factor (TNF)
, interleukin (IL)-6, and IL-8, increases in patients with sepsis; marked production causes organ failure and septic shock. We previously reported that ketamine suppressed lipopolysaccharide (LPS)-induced TNF-
production in mice. However, there are no reports on the effect of ketamine on cytokine production in human whole blood. Therefore, in this study, we investigated the efficacy of ketamine on LPS-induced TNF-
, IL-6, and IL-8 production and recombinant human (rh) TNF-
induced IL-6 and IL-8 production in human whole blood. After adding different doses of ketamine to whole blood, the blood was stimulated with LPS or rhTNF. After incubation, the plasma TNF-
activity and IL-6 and IL-8 concentrations were measured using the L929 cell cytotoxic assay or an enzyme-linked immunoassay. Ketamine significantly suppressed LPS-induced TNF-
production at concentrations >20 µg/mL. At concentrations >100 µg/mL, ketamine also significantly suppressed both LPS-induced and rhTNF-induced IL-6 and IL-8 production. In this study, we demonstrated that ketamine directly inhibits the production of proinflammatory cytokines such as TNF-
, IL-6, and IL-8 in human whole blood.
Implications: We found that ketamine suppressed lipopolysaccharide-induced tumor necrosis factor
, interleukin (IL)-6, and IL-8 production and recombinant human tumor necrosis factor-induced IL-6 and IL-8 production in human whole blood. Ketamine directly suppresses proinflammatory cytokine production.
This article has been cited by other articles:
![]() |
J. G. Bovill Anesthetic Pharmacology: Reflections of a Section Editor Anesth. Analg., November 1, 2007; 105(5): 1186 - 1190. [Full Text] [PDF] |
||||
![]() |
B. Beilin, Y. Rusabrov, Y. Shapira, L. Roytblat, L. Greemberg, I. Z. Yardeni, and H. Bessler Low-dose ketamine affects immune responses in humans during the early postoperative period Br. J. Anaesth., October 1, 2007; 99(4): 522 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pai and M. Heining Ketamine CEACCP, April 1, 2007; 7(2): 59 - 63. [Full Text] [PDF] |
||||
![]() |
R. Gurfinkel, D. Czeiger, A. Douvdevani, Y. Shapira, A. A. Artru, Y. Sufaro, J. Mazar, and G. Shaked Ketamine improves survival in burn injury followed by sepsis in rats. Anesth. Analg., August 1, 2006; 103(2): 396 - 402, table of contents. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. S. Shibakawa, Y. Sasaki, Y. Goshima, N. Echigo, Y. Kamiya, K. Kurahashi, Y. Yamada, and T. Andoh Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide Br. J. Anaesth., December 1, 2005; 95(6): 803 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Nagels, R. Demeyere, J. Van Hemelrijck, E. Vandenbussche, K. Gijbels, and E. Vandermeersch Evaluation of the Neuroprotective Effects of S(+)-Ketamine During Open-Heart Surgery Anesth. Analg., June 1, 2004; 98(6): 1595 - 1603. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sun, F. Li, J. Chen, and J. Xu Effect of Ketamine on NF-kappa B Activity and TNF-alpha Production in Endotoxin-Treated Rats Ann. Clin. Lab. Sci., April 1, 2004; 34(2): 181 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Taniguchi, H. Kanakura, Y. Takemoto, and K. Yamamoto The Antiinflammatory Effects of Ketamine in Endotoxemic Rats During Moderate and Mild Hypothermia Anesth. Analg., April 1, 2004; 98(4): 1114 - 1120. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Taniguchi, Y. Takemoto, H. Kanakura, Y. Kidani, and K. Yamamoto The Dose-Related Effects of Ketamine on Mortality and Cytokine Responses to Endotoxin-Induced Shock in Rats Anesth. Analg., December 1, 2003; 97(6): 1769 - 1772. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zilberstein, R. Levy, M. Rachinsky, A. Fisher, L. Greemberg, Y. Shapira, A. Appelbaum, and L. Roytblat Ketamine Attenuates Neutrophil Activation After Cardiopulmonary Bypass Anesth. Analg., September 1, 2002; 95(3): 531 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yu, Z. Zhou, J. Xu, Z. Liu, and Y. Wang Ketamine Reduces NF{kappa}B Activation and TNF{alpha} Production in Rat Mononuclear Cells Induced by Lipopolysaccharide In Vitro Ann. Clin. Lab. Sci., July 1, 2002; 32(3): 292 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kapur and R. Friedman Oral Ketamine: A Promising Treatment for Restless Legs Syndrome Anesth. Analg., June 1, 2002; 94(6): 1558 - 1559. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kawasaki, T. Kawasaki, M. Ogata, K. Nandate, and A. Shigematsu Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood : [Les isomeres de la ketamine suppriment la production de cytokine pro-inflammatoire induite par des superantigenes dans le sang complet humain] Can J Anesth, September 1, 2001; 48(8): 819 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lewis, B. Rogachev, G. Shaked, and A. Douvdevani The In Vitro Effects of Ketamine at Large Concentrations Can Be Attributed to a Nonspecific Cytostatic Effect Anesth. Analg., April 1, 2001; 92(4): 927 - 929. [Full Text] [PDF] |
||||
![]() |
T. Sakai, T. Ichiyama, C. W. Whitten, A. H. Giesecke, and J. M. Lipton Ketamine suppresses endotoxin-induced NF-kappaB expression Can J Anesth, October 1, 2000; 47(10): 1019 - 1024. [Abstract] [PDF] |
||||
|